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The need for alternative approaches to replace the in vivo rabbit Draize eye test for evaluation of eye irri-
tation of cosmetic ingredients has been recognised by the cosmetics industry for many years. Extensive
research has lead to the development of several assays, some of which have undergone formal validation.
Even though, to date, no single in vitro assay has been validated as a full replacement for the rabbit Draize
eye test, organotypic assays are accepted for speciﬁc and limited regulatory purposes. Although not for-
mally validated, several other in vitromodels have been used for over a decade by the cosmetics industry
as valuable tools in a weight of evidence approach for the safety assessment of ingredients and ﬁnished
products. In light of the deadlines established in the EU Cosmetics Directive for cessation of animal test-
ing for cosmetic ingredients, a COLIPA scientiﬁc meeting was held in Brussels on 30th January, 2008 to
review the use of alternative approaches and to set up a decision-tree approach for their integration into
tiered testing strategies for hazard and safety assessment of cosmetic ingredients and their use in prod-
ucts. Furthermore, recommendations are given on how remaining data gaps and research needs can be
addressed.
 2009 Elsevier Inc. Open access under CC BY-NC-ND license. 1. Introduction
According to the Organisation for Economic Co-operation and
Development (OECD) Guidelines for the Testing of Chemicals Test
No. 405: acute eye irritation/corrosion, eye irritation is deﬁned as
‘‘. . . the production of changes in the eye following application of
a test substance to the anterior surface of the eye, which are fully
reversible within 21 days of application”. The same guideline de-
ﬁnes eye corrosion as ‘‘. . . the production of tissue damage in the
eye, or serious physical decay of vision, following application of a
test substance to the anterior surface of the eye, which is not fully).
-NC-ND license. reversible within 21 days of application” (OECD TG 405, 2002). Dif-
ferent regulatory systems exist, e.g., within the European Union
(EU) (EU, 2004), United States and on a more global basis (UN,
2003) which classify substances based on the severity and persis-
tence of the eye responses (cornea, iris and conjunctiva) that they
produce. Such classiﬁcations translate into labelling of the sub-
stance and for products where required by legislation.
In general, topical eye irritants cause local effects on the front
structures of the eye e.g., cornea, conjunctiva, iris and lachrymal
system. The extent of involvement of these different ocular struc-
tures in irritation is a reﬂection of the severity of the response. Typ-
ically, slight irritants produce primarily conjunctival effects with
little or no corneal involvement. While conjunctival responses gen-
erally precede corneal responses, corneal injury is associated with
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mechanistic basis for ocular irritation using different chemical
classes comprising surfactants (anionic, cationic, and non-ionic),
acids, alcohols, aldehydes, alkalis and bleaches have shown that
depth of injury to the cornea, in the early hours after exposure, is
predictive of the eventual degree and duration of the ocular lesions
in the rabbit (Maurer et al., 2002; Jester, 2006). This research dem-
onstrated that slight irritants tend to affect only the superﬁcial cor-
neal epithelium, mild and moderate irritants affect epithelium and
superﬁcial stroma whilst highly moderate and severe irritants af-
fect deeper layers of the stroma (and possibly the endothelium).
In turn, the depth of injury is also related to the eventual degree
and recovery of the injury. Common mechanisms of injury causing
acute effects include membrane lysis, protein coagulation, saponi-
ﬁcation and action on macromolecules. Chemicals that react with
nucleic acids, mitochondrial proteins, or other cellular targets often
show a longer latency period between exposure and maximum
manifestation of damage to the cornea (Maurer et al., 2002; Jester,
2006).
Cosmetics may come into contact with the eye under condi-
tions of intended use or accidental exposure (e.g., in the case of
mascaras and shampoos, respectively). Both scenarios need to
be evaluated in a proper safety assessment, as stipulated in the
EU Cosmetics Directive (EU, 1976). Due to this potential exposure,
it is essential to assess the ocular safety of cosmetic ingredients
and/or ﬁnal cosmetic products. The rabbit Draize eye test (OECD
TG 405, 2002) is globally accepted as the standard regulatory
method for evaluating the eye irritation potential of substances
and has been used for several decades. An extensive number of
in vitro models have been developed and proposed as alternatives
to the rabbit Draize eye test. A overview of these methods is
available in a comprehensive review published by Eskes et al.
(2005). Several of these in vitro assays have been included in
six major validation or evaluation studies (EC/HO (Balls et al.,
1995), COLIPA (Brantom et al., 1997), BGA/BMBF (Spielmann
et al., 1993, 1996), CTFA (Gettings et al., 1991, 1994, 1996), IRAG
(Bradlaw et al., 1997) and MHW/JCIA (Ohno et al., 1994)) that
took place between 1991 and 1997. A review of these studies
(Balls et al., 1999) concluded that despite good reproducibility
and sensitivity of several of the in vitro assays for ocular irritation,
the predictive performance of each individual assay was not suf-
ﬁcient to fully replace the rabbit Draize eye test. Despite this,
organotypic assays (models that resemble the in vivo situation
in 3-D form or function or both) are widely used for speciﬁc, lim-
ited regulatory purposes. The Bovine Corneal Opacity and Perme-
ability (BCOP),1 Isolated Chicken Eye (ICE), Isolated Rabbit Eye (IRE)
and the Hen’s Egg Test on the Chorio-Allantoic Membrane (HET-
CAM) have been ofﬁcially accepted since 2004 by European author-1 BCOP, Bovine Corneal Opacity and Permeability; BfR, Bundesinstitut für Risik-
obewertung (German Federal Institute for Risk Assessment); BGA, Bundesgesund-
heitsamt (German Department of Research and Technology); BMBF,
Bundesministerium für Bildung und Forschung (German Federal Ministry of Educa-
tion and Research); COLIPA The European Cosmetic Association; CTFA, Cosmetic,
Toiletry and Fragrance Association; DSS, Decision Support System; EC/HO, European
Commission/British Home Ofﬁce; ECVAM, European Centre for the Validation of
Alternative Methods; EPAA, European Partnership on Alternative Approaches to
Animal Testing; ESAC, ECVAM Scientiﬁc Advisory Committee; EU, European Union;
GHS, Globally Harmonised System; HCE, Human corneal epithelium; HET-CAM, Hen’s
Egg Test on the Chorio-Allantoic Membrane; ICCVAM, Interagency Co-ordinating
Committee for the Validation of Alternative Methods; ICE, Isolated Chicken Eye; IRAG,
Interagency Regulatory Alternatives Group; MHW/JCIA, (Japanese) Ministry of Health
and Welfare/Japanese Cosmetic Industry Association; NC, not classiﬁed; OECD,
Organisation for Economic Co-operation and Development; (Q)SAR, (Quantitative)
Structure Activity Relationship; Reconstructed human Tissue (RhT); REACH, Regis-
tration, Evaluation, Authorisation and Restriction of Chemicals; TTC, Threshold of
Toxicological Concern; WoE, weight of evidence.ities for the classiﬁcation and labelling of severe eye irritants. More
recently, the European Centre for the Validation of Alternative
Methods (ECVAM) Scientiﬁc Advisory Committee (ESAC) issued
statements of scientiﬁc validity for BCOP and ICE as screening tests
for identiﬁcation of ocular corrosives and severe eye irritants (EC-
VAM, 2007). These statements support the outcome of the Inter-
agency Co-ordinating Committee for the Validation of Alternative
Methods (ICCVAM) Background Review Document activities for
these organotypic assays (ICCVAM, 2006). In order to identify irri-
tants over the entire potency range for all chemical classes, it is
generally accepted that a battery of alternative assays will be re-
quired. Furthermore, the cosmetics industry has a need for
in vitro assays that provide greater resolution and precision in
the mild to very mild range of eye irritancy than are offered by
the standard rabbit Draize eye test.
On 11 March 2009, two bans entered into force concerning ani-
mal testing related to cosmetics products in the European Union.
Both were decided in 2003 in the context of the 7th amendment
to the Cosmetics Directive (EU 2003), which, amongst other pur-
poses, aims at ensuring the safety of ingredients used in cosmetic
products. A ﬁrst ban concerns animal testing itself to assess the
safety of ingredients. A second ban prohibits the sale of cosmetic
products containing ingredients tested on animals. This ban is pro-
gressive, until it becomes a complete ban in March 2013 taking
into account scientiﬁc progress being made regarding repeat dose
tests for which alternative methods do not yet exist. The impact of
the ban on the use of alternative assays to replace animal tests for
the assessment of eye irritation after March 2009 was analysed at a
COLIPA scientiﬁc meeting organised by its Safety Assessment and
Eye Irritation Project Teams in Brussels on 30th January, 2008. Par-
ticipants included safety experts from a number of cosmetic com-
panies. Decision trees for safety assessment were developed using
the outcome of the discussions held during the meeting, in which
tiered testing strategies and the use of weight-of-evidence (WoE)
were considered major principles. Gaps and hurdles were also
identiﬁed and recommendations for further activities were
developed.2. Results and discussion
2.1. Current alternative approaches to the assessment of eye irritation
Current safety assessment practices make routine use of tiered
testing strategies based on a WoE approach. WoE approaches have
long been in use and have also been investigated by ECVAM in the
context of validation (Balls et al., 2006). The principle is that all
available information is considered in the assessment, in this case
of eye irritation. Such information may include, for example:
 Physicochemical properties.
 Historical in vivo animal data.
 In vitro data.
 Human data (clinical and post-market surveillance).
 Exposure.
If the information which is initially available is considered
insufﬁcient, a tiered testing strategy is pursued that allows for
the generation of additional data. Important elements may include
read-across approaches based on chemical domain (OECD Applica-
tion Toolbox (www.oecd.org)). Integrated testing strategies have
been applied in the chemical sector, and were recently re-evalu-
ated in the Registration, Evaluation, Authorisation and Restriction
of Chemicals (REACH) context (Grindon et al., 2008), as well as
the application of WoE approaches (e.g., OSIRIS project) (van Leeu-
wen et al., 2007).
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approach
There are several different data sources that are incorporated
into a WoE approach to evaluate eye irritation. A brief description
of how the information available from each of these data sources is
useful in a WoE approach to evaluate eye irritation without the use
of newly generated animal data is provided below.
2.2.1. Physicochemical properties
Information of relevance to eye irritation/corrosion can be in-
ferred from basic physicochemical characteristics of a substance
such as, but not limited to physical form (liquid, solid, gel), solubil-
ity, pH, pKa and molecular weight, ionisation potential, vapour
pressure, water solubility, critical micelle concentration. For exam-
ple, substances with ‘extreme’ pH values (P11.5 or 62) may have
strong local effects such as severe eye irritation/corrosion. Several
studies have investigated and conﬁrmed the usefulness of pH as a
predictor of corrosion (Worth and Cronin, 2001) and as an element
in tiered testing strategies (Worth, 2004). However, where extreme
pH is the only basis of identiﬁcation of a corrosive, it may also be
important to take into consideration the acid/alkaline reserve, a
measure of the buffering capacity of a chemical substance (Botham
et al., 1998; Young et al., 1994). The use of physicochemical prop-
erties as a starting point in a tiered strategy for evaluation of eye
irritation is provided as a supplement in the OECD guideline 405
for the testing of chemicals, acute eye irritation/corrosion (OECD
TG 405, 2002).
2.2.2. Historical in vivo animal data
Availability of historical animal data for chemicals with high
structural similarity is often useful for the eye irritation assess-
ment of a substance within the same chemical domain. When ani-
mal data are available on similar substances these data can be used
in a read-across approach to demonstrate that a substance under
consideration that is of the same chemical class is likely to produce
the same ocular responses. Such an evaluation is only possible
when sufﬁcient historical in vivo data for the chemical domain
are available and there are no additional structural alerts that are
considered likely to cause ocular effects.
Validated and accepted (Q)SAR approaches for eye irritation are
currently not available, in part due to eye irritation being a difﬁcult
endpoint to model in silico due to the complexity of the biological
mechanisms that may be involved in eye irritation.
2.2.3. In vitro data
There are a number of in vitro assays used within the industry
for purposes of screening and safety assessment of substances for
eye irritation. Tables 1 and 2 list a number of in vitro eye irritation
assays, together with a brief description of the assays, information
that is obtained from them, their validation status, and their appli-
cability based on current practices and scientiﬁc literature. Table 1
lists assays with regulatory acceptance and Table 2 without regu-
latory acceptance.
In vitro tests have been used routinely by cosmetic companies
for over a decade. They are typically used for early routine
screening in the development process of new ingredients/prod-
ucts and provision of safety assessment as part of an integrated
testing strategy for ingredients and ﬁnished products as they pro-
ceed to market. The in vitro assays are ideally used, usually in
combination, to assess classes of materials where the mode of ac-
tion (e.g., cell death, coagulation, saponiﬁcation, interaction with
macromolecules) to effect eye irritation is well understood. Con-
ﬁdence for such in-house use of these in vitro assays is dependent
on a number of factors such as the availability of appropriate
benchmarks, historical information on similar materials, anunderstanding of the limitations of the assay(s) and the technical
expertise of the user. For these reasons, such use of in vitro meth-
ods and their combination is often company-speciﬁc. As such,
application of these methods has allowed companies to eliminate
ﬁnished formulation testing using animals over a decade ago and
to evaluate to a large extent the eye irritation of ingredients in
cosmetic products.
2.2.4. Human data
2.2.4.1. Clinical studies. Human volunteer studies can be an integral
part of the overall safety assessment of a cosmetic product. This is
because it is possible to evaluate product compatibility in humans
by using clinical evaluations under the anticipated and foreseeable
uses.
Such studies are always conﬁrmatory in nature and are not haz-
ard identiﬁcation studies. They can only be conducted when the
WoE has demonstrated that a product is safe for eye exposure
but the judgement is that additional conﬁrmatory data would be
useful to the overall product safety assessment.
Ethical considerations, involvement of qualiﬁed personnel (e.g.,
ophthalmologists) and consideration of Good Clinical Practice
(GCP) guidelines and availability of in vitro eye irritation tests as
part of the pre-clinical evaluation are of paramount importance
when considering the conduct of human volunteer studies. Such
human volunteer studies may involve direct eye instillation or re-
peated peri-ocular application by the study investigator or product
use by the study participant under normal use conditions. In all
cases, objective assessment by an ophthalmologist and subjective
assessment by the study participant is conducted.
2.2.4.2. Human experience. Human experience can be derived from
different sources such as from in-house post-market surveillance
systems in which individual companies monitor the marketplace
for the occurrence of adverse event through consumer contact typ-
ically through provision of an on-pack contact number for the com-
pany. In addition, human experience can be derived from industry-
wide consumer follow-up systems and from national Poison Con-
trol Centres (PCCs) on reported accidental exposures.
2.2.5. Exposure
Finished products are a combination of several different chem-
icals each present at a speciﬁc concentration. As such, it is impor-
tant to understand the eye irritation potential of the ingredients at
in-use concentrations in addition to the neat form. Exposure con-
siderations that need to be taken into account are type of formula-
tion (e.g., skin care, shampoo), area of application (e.g., face, scalp,
axilla, body) and frequency of application (several times a day,
intermittently). In cases where very low concentrations of chemi-
cals are present in a ﬁnished product, an exposure-based assess-
ment may allow the conclusion that any local effects such as eye
irritation are highly unlikely to occur.
2.3. Alternative approaches not yet validated and/or under
development
2.3.1. COLIPA eye irritation programme
To address development of alternative methods based on mech-
anistically relevant biological events, the European Cosmetics
Association (COLIPA) through its overall Alternatives to Animal
Testing (AAT) initiative has in place a programme for the develop-
ment of in vitro assays for eye irritation that is managed by the Pro-
ject Team PT-Eye Irritation. The overall programme incorporates
three core elements: (1) method development/optimisation of
existing models to validation; (2) collaborative activities with
external partners; and (3) integrated research projects that are
conducted in collaboration with academia. The short-term need
Table 1
A summary of in vitro assays with ofﬁcial regulatory acceptance.
Assay
Bovine Corneal Opacity and Permeability (BCOP)
assay
Isolated Chicken Eye (ICE) formerly known as
Chicken Enucleated Eye Test (CEET)
Isolated Rabbit Eye (IRE) assay Hen’s Egg Test on the Chorio-Allantoic Membrane
(HET-CAM) assay (different protocols)
Ocular effect Corneal damage Corneal damage Corneal damage Conjunctival damage
Evaluation end
point
Corneal opacity, thickness and permeability.
Histopathology recommended to be incorporated
as a routine endpoint
Corneal opacity, swelling and permeability
Histopathology recommended to be incorporated
as a routine endpoint
Corneal opacity, swelling and integrity,
barrier function. Histopathology
recommended to be incorporated as a
routine endpoint
Vascular changes in the egg’s CAM (haemorrhage,
lysis) and coagulation, (hyperaemia)
Validation
status
ECVAM Statement of scientiﬁc validity for
identiﬁcation of severe irritants/ocular corrosives
(April 2008). Additional data review by ECVAM/
ICCVAM to evaluate usefulness of BCOP to identify
levels of irritancy lower than severe
ECVAM Statement of scientiﬁc validity for
identiﬁcation of severe irritants/ocular corrosives
(April 2008). Additional data review by ECVAM/
ICCVAM to evaluate usefulness of ICE to identify
levels of irritancy lower than severe
None (further review is recommended) None (further review is recommended; a
retrospective validation of HET-CAM data is
currently under discussion)
Regulatory
acceptance
Severe eye irritants/ocular corrosives (GHS Cat 1/R41
classiﬁcation)
Severe eye irritants/ocular corrosives (GHS Cat 1/R41
classiﬁcation)
Severe eye irritants/ocular corrosives (GHS Cat
1/R41 classiﬁcation)
Severe eye irritants/ocular corrosives (GHS Cat 1/R41
classiﬁcation)
Accepted by EU to identify ocular corrosives and
severe irritants (July 2004)
Accepted by EU to identify ocular corrosives and
severe irritants (July 2004)
Accepted by EU to identify ocular corrosives
and severe irritants (July 2004)
Accepted by EU to identify ocular corrosives and
severe irritants (July 2004)
Accepted by US regulatory agencies to identify
ocular corrosives and severe irritants (June 2008)
Accepted by US regulatory agencies to identify
ocular corrosives and severe irritants (June 2008)
On-going development of an OECD guideline based
on the current regulatory acceptance (for severe
irritant/ocular corrosive)
On-going development of an OECD guideline based
on the current regulatory acceptance (for severe
irritant/ocular corrosive)
Irritancy range
detected
according to
literature
Moderate, severe and very severe. Histology
proposed to improve predictive capacity for severe
irritants identiﬁed as false negatives1 and for
greater discrimination of mild/moderate irritants
such as surfactants and surfactant-based products2
surfactant-based rinse-off personal care 2
Severe and non-irritants1,3 Severe1 Mild to moderate for surfactant-
based formulations 1,4,5
Mild to non-irritating, different protocols have
been adapted to materials with different physico-
chemical properties1 Severe irritants 6,7
Chemical class
according to
literature
Wide range of physical forms and solubilities1
Chemicals (alcohols, ketones, carboxylic acids,
heterocyclic compounds over-predicted) and
formulations1. Chemicals and formulations
associated with highly fragranced products1
Wide range of physical forms and solubilities such
as liquids, pastes and gels. Surfactant-based
formulations3
Alkaline materials, anionic and cationic
surfactants1. Formulations in the cosmetic
and pharmaceutical industries1. Surfactant-
based formulations1,4
Surfactants7. Many types of ingredients and
formulations (rinse-off, leave on, water soluble/
non-soluble, solids)6,7 especially suited for
surfactants and surfactant-based formulations6,
biological membranes (dyes, pigments)1,6,7
Oxidisers (hair dye formulations)1. Personal care
products (e.g., shampoos, deodorants)1
Surfactant-based formulations8
Limitations Not as sensitive in distinguishing between mild
irritants with the standard protocol1
Underestimation of substances acting primarily on
the iris or the conjunctiva1 unless combined with
histology2
Possible limitation for solids1 Possible limitation for solids1 Possible limitation for solids and with substances
that stain1
To note: Table 1 is a compilation of recent information abstracted from the scientiﬁc literature. As such, it is meant to provide the reader with an overview of the type and quantity of information available in the public domain on
reported uses of in vitro eye irritation assays. Table 1 is not meant to be a comprehensive overview of all of the information available. Information available up to 2005 is comprehensively reviewed in Eskes et al. (2005).
References are cited in Table 1 using a sufﬁxed number. The full citation is provided in the reference section.
1Eskes et al. (2005), 2Cater and Harbell (2006), 3Prinsen (1996), 4Cooper et al. (2001), 5Jones et al. (2001), 6Spielmann et al. (1997), 7Steiling et al. (1999), 8Cater and Harbell (2008), 9Bagley et al. (1994).
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summary of in vitro assays without ofﬁcial regulatory acceptance so far.
say Ocular effect Evaluation end point Validation status Reported uses in the peer-reviewed scientiﬁc literature
Irritancy range detected Chemical class
rioallantoic
Membrane
Vascular assay
(CAMVA)
Conjunctival
damage
Vascular changes in the isolated CAM:
Haemorrhaging, hyperaemia, inhibition of
blood ﬂow
None Best for mild to moderate irritation;
limitations at the lower end and for severe
irritants1,4
Broad range of formulations (rinse-off and
leave-on) and ingredients (solvents, alcohols,
surfactants, acids, bases)2,3,4
man Corneal
Epithelium (HCE)
SkinEthicTM
Corneal damage Cytotoxicity based on MTT reduction
expressed either as% viability or as ET50
Entered into a formal validation
study (end 2008). ESAC peer
review expected in 2009
Slightly irritant, moderately irritant and
irritant5,6 Irritant versus non-irritant6 Non-
irritating, very slightly irritating, slightly
irritating, irritating and very irritating7
Broad range of chemicals and product
formulations of different physical form
including liquids and solida5,7,8,9,10. Raw
materials (surfactants esters, alcohols, ketones,
miscellaneous) and cosmetic products (alcohol-
based products, bath and cleaning products,
skin and suncare products make-up products5
Hydrophilic and hydrophobic chemicals, dyes,
polymers, silicones, solvents6
Surfactants5,7,8,9,10. Surfactant-based shampoos
and conditioner6. Raw materials including
surfactants, polymers silicones, dyes, solvents,
vegetable extracts, preservatives9,10
atTek EpiOcularTM
assay
Corneal damage Cytotoxicity based on MTT reduction
expressed either as% cell viability or as
ET50
Entered into a formal validation
study (end 2008) ESAC peer
review expected in 2009
Mild to moderate1 Non-irritant versus
irritant11 Mild to moderate and potentially
severe
Broad range of chemicals and product
formulations of different physical form
including hydrophilic and hydrophobic
materials1,8,11,12. Oversensitive to alcohols and
esters. Not appropriate for highly volatile
liquids, organic solvents and certain classes of
reactive chemicals (e.g., peroxides)1. Raw
materials (surfactants, hydrocarbons, amines,
esters and ketones)11. Finished products
(shampoo, bar soap, hair conditioner, skin
creams, toothpaste antiperspirant/deodorant)12
Surfactant-based shampoos13,14 and shampoos
and conditioners8
utral Red Release
assay (different
cell types possible)
Corneal damage Cytotoxicity measured by release of the
dye Neutral Red into a mono-layer cell
cultures (plasma membrane damage, loss
of lysosomal integrity)
Ongoing Validation
Management Group (VMG)
review for post hoc validation
ESAC peer review expected in
2009
Especially suited for the mild to very mild
range1 Accepted by local authorities in France
for evaluation of eye irritation of ﬁnished
products
Especially suited for surfactants and surfactant-
based and water-soluble or miscible substances
and formulations, including personal care
materials1,15, Wide range of cosmetic
formulations (leave-on and rinse-off) and
ingredients (alcohols, surfactants, ketone, bases,
acids, esters)16,17. Hair-care formulations:
shampoos and conditioners8
utral Red Uptake
assay
Corneal damage Cytotoxicity measured by inhibition of
uptake of the dye Neutral Red into mono-
layer cell cultures
Not subject to validation Mild irritants1 Surfactants1,18,19. Limitations for substances
with extremely high or low pH, high reserve
acidity or alkalinity, highly volatile, coloured1
d Blood Cell (RBC)
assay
Corneal damage Cytotoxicity based on haemolysis and
oxyhaemaglobin denaturation in Red
Blood Cells
Ongoing Validation
Management Group (VMG)
review for post hoc validation
ESAC peer review expected in
2009
Very mild and non-mild1 Surfactants and surfactant-based formulations
such as shampoos and personal care
products7,19,20,21,22,23,24
uorescein Leakage
assay or Trans-
Epithelial
Permeability (TEP)
assay
Corneal damage Permeability of ﬂuorescein through a
monolayer of epithelial cells in culture
that have formed tight junctions and
desmosomes
Ongoing Validation
Management Group (VMG)
review for post hoc validation
ESAC peer review expected in
2009
Mild to moderate1 Surfactants, surfactant-based
formulations1,18,25,26 and alcohols8,19
(continued on next page)
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as soon as possible are addressed by parts 1 and 2 whilst the longer
term need to have available in vitro assays based on a better under-
standing of mechanisms of eye irritation is addressed by part 3 of
the programme.
Brief details of the approach and projects within the core ele-
ments of the COLIPA programme are:
2.3.1.1. Method development/optimisation of existing models. The
method development/optimisation of current in vitro assays within
the COLIPA PT-SCAAT (Project Team of the Steering Committee on
Alternatives to Animal Testing) eye irritation programme is fo-
cused on Reconstructed human Tissue (RhT) models. Several RhT
models are available with some being more advanced in both
development and availability than others.
 Two of the most advanced models currently available are the
SkinEthicTM Human Corneal Epithelium (HCE) model (derived
from Human Corneal Epithelium) and the MatTek EpiocularTM
model (derived from human keratinocytes). Recent work on
these models has been led by industry in collaboration with
the test method developers to expand the data available for
predictive capacity and reproducibility (within and between
laboratories) using optimised protocols. COLIPA is now engaged
with ECVAM in a formal validation study for these two RhT
models.
 Other RhT eye irritation models under development have
reported improved barrier function capability over some of the
commercially available models. COLIPA is engaged in under-
standing whether use of barrier function as an endpoint is useful
to measure in an RhT assay for evaluation of eye irritancy at the
lower (non-irritant/very mild) end of the irritancy range.
2.3.1.2. Integrated analysis to deﬁne batteries of in vitro assays. All
assays have speciﬁc domains of applicability whether this relates
to range of irritancy or to types of chemical classes. If the deter-
mined applicability domain does not fully cover the purpose of
the safety assessment, combinations of assays are likely to be
needed. Today, combinations of in vitro assays are used by individ-
ual companies as an integral part of their safety assessments (see
Section 4). Likewise, validation efforts focus increasingly on testing
batteries since it is generally accepted that no single assay will
fully replace the rabbit Draize eye test.
2.3.1.3. External collaboration. Equally important to achieve vali-
dated in vitro methods is collaboration between industry, acade-
mia, external scientiﬁc organisations and regulators.
 COLIPA is working with ECVAM by active mutual participation
in both COLIPA and ECVAM Eye Irritation Task Forces.
 COLIPA is providing ECVAM with support for post hoc statistical
analysis of current in vitro methods and development of
approaches for integrated analysis to deﬁne batteries of
in vitro assays via the funding of an independent biostatistician.
This latter activity is further discussed in Section 2.3.3 below.
2.3.1.4. Research programme. Building on the experience of earlier
validation studies and scientiﬁc workshops the research pro-
gramme is focused on identiﬁcation of in vitro endpoints related
to the dynamics of injury and recovery that are more predictive
for in vivo eye irritation effects that occur in humans. This will en-
able the development of prediction models for pre-validation of
new or improved in vitro methods that would proceed to formal
validation.
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composed of three integrated research projects: (1) development
of an in vitro model of excised corneas maintained in culture to al-
low observation of injury/recovery after chemical exposure to
investigate whether kinetics/patterns of change in physiological
function and signals of injury released from the cornea in vitro
can predict a chemical’s potential to damage the eye with a focus
on recovery; (2) development of sequentially built bioengineered
3-D multi-layer corneal constructs consisting of epithelium, stro-
ma and endothelium to better understand underlying mechanisms
of action to enable identiﬁcation of endpoints related to magnitude
of injury and quality of repair in human immortalised cells and 3-D
human conjunctival and corneal constructs; and (3) a preliminary
genomics project using a pattern recognition approach to identify
new endpoints for injury and repair that builds on corneal models
for potential use in current/future in vitro assays.
The goal of the research programme is to have available a model
that measures depth of injury and recovery. As such, the ongoing
work is focussed on continued development of multilayer corneal
models such as isolated eyes, isolated corneas and 3-D bioengi-
neered corneal constructs and incorporation of evaluation param-
eters that measures depth of injury as this relates to extent of
recovery.
2.3.2. In silico approaches
Eye irritation is a difﬁcult endpoint to model in silico because of
the complexity of the biological mechanisms that may be involved
(Maurer et al., 2002; Jester, 2006). Most approaches have therefore
modelled eye irritation resulting from physical effects, such as pen-
etration of the ocular tissues or corrosion. The most commonly
used approaches have focused on the development of: (a) tradi-
tional quantitative models (in which a measure of eye irritation po-
tency is predicted); (b) classiﬁcation models (in which a
classiﬁcation of eye irritation potential is predicted); (c) simulation
of molecule-membrane interactions; (d) neural network models in
which non-linear QSARmodelling techniques are employed; and e)
expert system approaches (e.g., TOPKAT, the BfR rules for the pre-
diction of skin irritation (BfR), Derek (LHASA Ltd) and TOPKAT). A
Decision Support System (DSS) for the prediction of several toxico-
logical endpoints has been developed by the German Bundesinsti-
tut für Risikobewertung (BfR). With regard to the prediction of eye
irritation/corrosion, the DSS contains 31 physicochemical exclu-
sion rules based on molecular weight, octanol–water partition
coefﬁcient, lipid/aqueous solubility and melting point, and 27
inclusion rules that deﬁne structural alerts potentially responsible
for eye irritation and/or corrosion. A substructure is considered
‘‘reactive” based on the classiﬁcation and labelling of the majority
of its molecules (e.g., aliphatic monoalcohols) (Gerner et al., 2005;
Tsakovska et al., 2007). This system was submitted to ECVAM for
consideration to enter the validation process and is currently under
review.
2.3.3. External validation oriented activities
ECVAMorganised in 2005 aworkshop inwhich experts fromaca-
demia, industry and regulatory authorities developed an approach
that uses in vitro assays in combination alongwith anunderstanding
of physicochemical parameters to evaluate the eye irritation of a
substance. This strategy is called the Bottom–Up and Top–Downap-
proach and was developed to be applicable to chemicals in general
(Bottom–Up and Top–Down approach: Eye irritation testing strat-
egy to reduce and replace in vivo studies. Scott et al., submitted for
publication). It relies, as a ﬁrst step, on using physicochemical
parameters to predict whether a substance would be expected to
be an eye irritant or not. This decision drives the choice of the ﬁrst
in vitro assay to be conducted. Substances predicted to be of no or
low eye irritation potential would ﬁrst be tested in an in vitro assaymost suited to thedetectionof nonormild irritantswhilst those pre-
dicted to be severe eye irritants would ﬁrst be tested in assays most
suited for that purpose e.g., BCOP, ICE. This ﬁrst in vitro assay is then
followedby a second in vitro assay to conﬁrm irritancy status of sub-
stances identiﬁedasnot severe in theTop/Downtestingscenarioand
those identiﬁedas irritant in the Bottom/Up testing scenario. It is the
combinationof the two in vitro assays that can thenbeused toﬁnally
clarify the eye irritationpotential and if needed regulatory classiﬁca-
tion of a substance (GHS category 1 and2 (GloballyHarmonised Sys-
tem; a new legislation, recently approved to be implemented in the
EU (EU, 2008)); R41, R36, NC according to the current EU classiﬁca-
tion system). In order to implement this approach, there is a need to
have available a number of validated in vitro assays and amethod of
statistical analysis to determine the conﬁdence of predictive capac-
ity that can be derived from combinations of in vitro assays. A num-
ber of activities are ongoing to address this in terms of: (1) new (RhT
assays validation study) and (2) retrospective (currently available
cell function and cytotoxicity assays (Cytosensor, Red Blood Cell
(RBC), Neutral Red Release (NRR), Fluorescein Leakage (FL) review)
validation activities of in vitro assays. These activities as they relate
to the new and retrospective validation activities for in vitro assays
are listed inTable2. Furthermoredevelopmentof the statistical tools
to support this integrated analysis will need to occur.
Along similar lines, the European Partnership on Alternative Ap-
proaches to Animal Testing (EPAA) and ECVAM, in a joint effort,
held a workshop (EPAA, 2008) on integrated testing strategies
which started to address the validation of integrated testing strat-
egies and included the application of integrated analysis for deﬁni-
tion of combinations of in vitro assays.
2.3.4. Other approaches
Another approach that has been suggested is use of a ‘‘Thresh-
old of Toxicological Concern-like (TTC-like) approach”. This refers
to universal exposure thresholds of chemical exposure in general
similar to the TTC approaches developed for systemic effects
(Kroes et al., 2004, 2007). Whereas thresholds of concern are eval-
uated by safety assessors for speciﬁc substances and products on a
routine basis, a universal threshold concept has not been system-
atically explored for eye irritation to date.3. A tiered approach for eye irritation assessment
3.1. Decision tree for hazard assessment
A decision tree for eye irritation hazard assessment is outlined
in Fig. 1. This is a tiered iterative approach based on a number of
steps. It should be noted that decisions in this tiered approach take
into account both in vitro assays that already have regulatory
acceptance and those that are described in the scientiﬁc literature
and based on industry experience as being ‘‘suitable for purpose”.
Such industry experience is typically based on individual company
use of the in vitro assay with speciﬁc classes of chemicals that pro-
vide conﬁdence for its predictive capacity relative to the substance
under evaluation.
The different steps in the decision tree for hazard identiﬁcation
are as follows:
Step 1: Perform a WoE evaluation of all available information,
including for example physicochemical properties and ‘read-
across’ to other structurally similar chemicals with known eye irri-
tation potential to answer the question ‘‘Is this substance likely to
be corrosive to skin?”. If the answer to this question is ‘‘yes”, the
substance is considered as corrosive and by default, judged as a se-
vere eye irritant. If the answer to this question is ‘‘no”, either con-
sider it as a severe irritant as a worst case assumption, though not
conﬁrmed by testing, or proceed to Step 2.
Fig. 1. Decision tree approach proposed to evaluate ingredients for hazard identiﬁcation using alternative eye irritation assays.
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mine whether the substance is a severe eye irritant to answer the
question ‘‘Is the severe eye irritancy of the substance conﬁrmed?”
BCOP and ICE are organotypic assays for which both external vali-
dation status and regulatory acceptance are already ofﬁcially avail-
able for their use to positively identify severe eye irritants. Other
organotypic models, the HET-CAM and IRE assays, are also ac-
cepted by EU authorities for the classiﬁcation of severe irritants.
If the outcome of the organotypic assay indicates that the sub-
stance is a severe eye irritant, the result of Step 1 is conﬁrmed. If
the organotypic assay does not indicate severe eye irritancy of
the substance, in-house company experience is needed to support
prediction of irritancy levels of less than severe in order to move to
Step 3. It is important to consider the expected mode of action of
the test material. When evaluating the routine endpoints in the
organotypic assays, histological observations can improve the
interpretation.
Step 3: Conduct an in vitro assay for eye irritation to answer the
question ‘‘Is the substance an eye irritant (less than severe)?”. Thechoice of assay(s) need to take into account its applicability do-
main and requires experience with the chemical class to be evalu-
ated. The outcome of assay(s) in the WoE approach will indicate
whether the substance is considered an eye irritant or not irritating
to the eye.
It should be noted that decisions in this tiered approach take
into account assays that already have regulatory acceptance as
well as those that are described in the scientiﬁc literature as being
suitable and/or those that industry has experience with (in-house
qualiﬁcation). Regulatory acceptance information is included in
the footnotes of Fig. 1.
Tables 1 and 2 provide an overview of in vitro eye irritation as-
says and their application based on peer-reviewed literature whilst
Table 1 summarises the regulatory status of several of the assays.
3.2. Decision tree for safety assessment
A decision tree for safety assessment of ingredients using alter-
native eye irritation models is outlined in Fig. 2. As for hazard iden-
Fig. 2. Decision tree approach proposed to evaluate ingredients identiﬁed as non-irritant, irritant or severe irritant (in Fig. 1) for safety assessment using alternative eye
irritation models.
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approach. The starting point of the safety assessment for ingredi-
ents in cosmetic products is hazard identiﬁcation as presented in
the decision tree detailed in Fig. 1.
It should be noted that, as for hazard identiﬁcation, decisions in
this tiered approach for safety assessment of substances take into
account both in vitro assays that already have regulatory accep-
tance and those that are described in the scientiﬁc literature and
based on industry experience as being suitable for purpose. Such
in-house experience is typically based on individual company use
of the in vitro assay with speciﬁc classes of chemicals that provide
conﬁdence for its predictive capacity relative to the material under
evaluation. Very often, in vitro tests are performed with an ingredi-
ent in the context of a formulation in order not only to obtain infor-
mation on the neat ingredient, but at the same time on the irritant
potential of the actual composition of ingredients. This involvesuse of a comparative approach in which benchmark products are
included in the test.
The different steps in the decision tree for safety assessment are
as follows:
3.2.1. If the substance is identiﬁed as a severe eye irritant (Section 3.1)
Step 1: Conduct an organotypic in vitro eye irritation assay
listed in Table 1 on the diluted substance to answer the question
‘‘Is the substance severely irritant at use concentration?”. If the
answer is ‘‘yes”, use of this substance at this speciﬁc concentra-
tion in cosmetic products may not be possible. A severe irritant
can also be tested at usage concentration in a formulation using
organotypic in vitro eye irritation assay(s) to address that dilution
and formulation effects may decrease the potential for eye irrita-
tion or conﬁrm that the substance in formulation remains a severe
eye irritant. Formulations need to have an acceptably low eye irri-
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tal exposure.
If the diluted chemical does not cause severe eye irritation, pro-
ceed to Step 2.
Step 2: Conduct further in vitro tests covering the irritancy
range from non- to moderate irritant to answer the question
‘‘Is the substance irritant or non-irritant at usage concentra-
tion?”. This may take the form of testing diluted substance alone
or at usage concentration in formulation. The choice of assay(s)
needs to take into account its applicability and requires experi-
ence with the chemical class/formulation category to be evalu-
ated. The outcome of assay(s) in the WoE approach will
indicate whether the diluted substance/substance at usage con-
centration in formulation is considered an eye irritant or not irri-
tating to the eye. If the answer to this question is ‘‘yes” a
comparison is made with benchmark substances/formulations
to determine acceptability for continued development/marketing
and whether additional eye irritant labelling measures are re-
quired, or re-formulation needed. If the answer is ‘‘no”, no fur-
ther evaluation is required.
As mentioned above, decisions in this tiered approach take into
account assays that already have regulatory acceptance as well as
those that are described in the scientiﬁc literature as being suitableTable 3
Use examples based on information from 11 companies.
Assay(s) Ingredient
HET-CAM Various ingredients8 (not routinely performed, but data on vario
substances is available and has been used in validation studies)
HET-CAM + RBC
(1 h)
Botanicals (for several extracts like propylene glycol and glycero
CAM is over-predictive and therefore not suitable), polymers, si
(RBC depending on solubility), natural and mineral oils (RBC dep
on solubility), UV ﬁlters (RBC depending on solubility), emulsiﬁ
HET-CAM + NRR Botanicals, polymers, silicones, natural and mineral oils, solvent
10%), surfactants (up to 10%), emulsiﬁers, perfume oils. For som
ingredients containing more than 10% of surfactants, NRR test i
predictive, in these speciﬁc cases the HCE model is used4
HET-CAM + HCE
HET- CAM + HCE + BCOP
BCOP
BCOP + CAMVA
EpiOcularTM
(MatTek)
Pigments, silicones11
EpiOcularTM + ICE Botanicals; [colorants (primarily ICE, may include EpiOcularTM)]1
EpiOcularTM + RBC Surfactants (10 min-RBC) and in special cases EpiOcular)2
ICE Alkalis, colorants (primarily ICE, may include EpiOcular)11
ICE + cytosensor Surfactants11
NRR + HCE
IRE Various types of ingredients, especially as screen for severe irrit
only occasionally for safety assessment, but routinely for occup
hazard assessment7
HCE (3-D cornea
model,
SkinEthicTM)
Solvents (>10%), surfactants (>10%)4 Most ingredients; silicones
limitation (combination with HET-CAM + BCOP to enhance sens
predictive performance)6 Various types of ingredients; only occa
for safety assessment, but routinely for occupational hazard asses
TEP
The sufﬁxed number after each entry identiﬁes an individual company’s response.for purpose (see Tables 1 and 2 for additional information on assay
application and regulatory status of different assays).
Once the eye irritation proﬁle of the substance at use concentra-
tion is established, in some instances, it is desirable to obtain more
information about formulations that are used repeatedly around
the eye area. In these circumstances, conﬁrmatory human testing
of such formulations may be considered provided that a safety
assessment is available that supports this level of human exposure.
If the result indicates that the substance is irritant (less than se-
vere) (Section 3.1): Step 1: Conduct in vitro tests covering the irri-
tancy range from non- to moderate irritant to answer the
question ‘‘Is the substance irritant or not irritant at usage concen-
tration?”. The outcomes from this test are handled in the same way
as those from Step 2 for substances identiﬁed as severe.
If the result indicates that the substance is not an irritant (Section
3.1): if additional information is desirable, in vitro eye irritation as-
says that cover the range non- to moderate irritant may be consid-
ered for testing the substance at usage concentration in
formulation. This could be considered if formulation effects could
be suspected to alter the irritancy proﬁle of the substance at usage
concentration. The in vitro assays for this purpose are chosen on
the same basis as described above in Step 2 for severe irritants.
The outcome of in vitro assays will conﬁrm the non-irritancy ofProducts (containing speciﬁc ingredients)
us
3
Used mainly to assess surfactant-based cosmetic products. However,
other categories of ingredients are also contained in such formulations
and then also covered by the assessment3 Various types of formulations5
Rarely used for formulations9
l HET-
licones
ending
ers2
Alkalis, botanicals (for several extracts e.g., propylene glycol and glycerol
HET-CAM is over-predictive and therefore not suitable), pigments,
polymers, silicones, natural and mineral oils, UV ﬁlters, solvents (not for
higher concentrations), emulsiﬁers2
s (up to
e
s over-
Perfume oils; rinse-off formulations. When discrepancies are observed
the two methods, HCE is used4 Various formulations8
Surfactants4
Silicones6
Highly alkaline formulations1 Used mainly to assess surfactant-based
cosmetic products. However, other categories of ingredients are also
contained in such formulations and then also covered by the
assessment3
Various types of formulations5
Botanicals, colored formulas (hair dyes NA), pigments, polymers,
preservatives, silicones, solvents, surfactants (if not highly alkaline)1
EpiOcular is used for personal care products that are expected to be non-
irritating to mild3 Botanicals, pigments, silicones, UV ﬁlters, polymers,
emulsiﬁers, perfume oils, preservatives (face creams and colour
cosmetics); leave-on formulations, other formulations (hair sprays,
deodorants, antiperspirants)11 Surfactant-based formulations
(benchmark approach for baby and adult shampoos)10
1 [Colorants (primarily ICE, may include EpiOcularTM)]11
Solvents (for higher solvent concentrations), Surfactants (10 min-RBC
and in special cases EpiOcular)2
Alkalis, colorants (primarily ICE, may include EpiOcular)11
Surfactants, preservatives (surfactant-based formulations); rinse-off
formulations11
Leave-on formulations4
ants;
ational
Various types of formulations10
with
itivity/
sionally
sment7
Mascara: due to the galenic of this kind of product, only the HCE model
is suitable4
Various types of formulations (Surfactant-based or generally used in the
eye area)9
P. McNamee et al. / Regulatory Toxicology and Pharmacology 54 (2009) 197–209 207the substance at use concentration in formulation or that formula-
tion effects have increased the irritation potential.
Again, as described above, conﬁrmatory human testing can be
considered as necessary once the safety assessment for eye irrita-
tion is complete.
4. Examples of the use of in vitro assays as part of the decision
tree approach
Eleven manufacturers of cosmetic products, including major
companies, gave feedback on their use of in vitro assays to give
an overview of which assays are typically used for safety assess-
ment. Despite a lack of formally validated and accepted assays be-
yond the organotypic assays for speciﬁc and limited regulatory
purposes, multiple in vitro assays are routinely used for this pur-
pose. Table 3 provides examples of assays or combinations of as-
says that are used to evaluate the eye irritation potential of
cosmetic ingredients or products.
The approach typically used by companies to deﬁne the assay or
combination of assays to be used for evaluation of eye irritation is
based on combining knowledge/information from several different
sources. These include:
 Information for individual assays on ‘‘suitability for purpose”
from:
 Peer-reviewed scientiﬁc literature and previous validation/eval-
uation studies that deﬁne the predictive capacity of an assay in
terms of range of irritancy and/or chemical class. Such informa-
tion would also include any limitations that are known for the
assay (e.g., chemical class, physical form). Uses of in vitro assays
for speciﬁc product/ingredient types are indicated in Tables 1
and 2.
 In-house experience gained from use of the assay(s) that may
relate to peer-reviewed literature and previous validation/eval-
uation studies. Such experience is typically in the context of for-
mulation testing since it is the ﬁnished product to which a
consumer is exposed. This is based on a comparative toxicology
approach in which appropriate benchmark products are also
included. Collation of these data over a period of time increases
the reliability to support practical application of an assay/com-
bination of assays tailored to a company’s product ingredients.
Uses of in vitro assays for speciﬁc product/ingredient types are
indicated in Tables 1–3.
 Information on the proposed mechanism by which the ingredi-
ent/product causes eye irritation. It was deﬁned earlier that
mechanisms of injury causing acute effects include membrane
lysis, protein coagulation, saponiﬁcation and action on macro-
molecules (Maurer et al., 2002; Jester, 2006). Examples of sub-
stances that act by these mechanisms are surfactants
(membrane lysis), acids, alkalis and organic solvents (coagula-
tion), alkalis (saponiﬁcation) and bleaches/peroxides (action on
macromolecules). An example here would be the use of organo-
typic assays for evaluation of surfactant-based formulations.
 Information on the design and properties of the in vitro assay to
enable choice of assay(s) based on mechanistic understanding of
eye irritation. This relates to understanding of:
 The in vivo endpoint that the in vitro assay is designed to
model.
 The structure of the in vitromodel for example whether it is
a single monolayer of cells (Fluorescein Leakage); a strati-
ﬁed epithelium (RhT), a complete cornea (BCOP), whole
eye (ICE).
Current knowledge supports that area/depth of corneal injury
are principal factors in early responses and eventual repair afteraccidental eye exposure and that physiological changes and
inﬂammation are secondary responses. Slight irritants tend to
affect only the superﬁcial corneal epithelium, mild and moderate
irritants affect epithelium and superﬁcial stroma whilst highly
moderate and severe irritants affect deeper layers of the stroma
(and possibly the endothelium). On this principle, in vitro models
that include a stroma (e.g., BCOP, ICE) are more likely to be able
to detect severe irritants whilst those based on epithelium only
(RhT assays) are likely to predict better at the lower to middle
range of irritancy.
As such, it is through a collation of information as detailed
above on the speciﬁc in vitro assays, experience with conduct of
the assays, and use of appropriate benchmark controls that allows
companies to choose combinations of assays that are targeted,
complementary to each other and appropriate for the evaluation
of eye irritation for speciﬁc classes of ingredients/product types.
5. Future needs
5.1. Validated and regulatory accepted in vitro eye irritation assays
Formal validation of in vitro assays for their speciﬁc domains of
applicability and acceptance by the regulatory authorities in order
to predict across the range of eye irritancy for different chemical
classes.
5.2. Optimization of current assays
Continued development of current assays using different evalu-
ation endpoints to extend their domain of applicability.
5.3. Dose–response considerations
Investigation of current or newly developed methods to ﬁnd
more sensitive evaluation parameters to enable better discrimina-
tion at the low irritancy range (mild and non-irritants).
5.4. Integrated analysis
Today, companies assess the eye irritation potential of ingredi-
ents and formulations using speciﬁc combinations of in vitro assays
that are based on experience. This approach should be further
developed and reﬁned through use of statistical tools such as inte-
grated analysis that objectively deﬁnes predictive performance of
test combinations. It is anticipated that as more assays are formally
validated, they will be incorporated into in vitro batteries using
integrated analysis, a process which itself may be subject to ofﬁcial
acceptance criteria.
5.5. Focus on mechanistically-based assays
Development up to scientiﬁc validation of in vitro assays that
are based on a better understanding of mechanisms of eye irrita-
tion, especially with focus on recovery.
5.6. (Q)SAR validation
Further evaluation of emerging (Q)SAR models for eye irritation.
6. Conclusions
There are a number of alternative models available and already
established within the cosmetics industry which can be used to as-
sess the potential of cosmetic ingredients to cause eye irritation,
although none are formally validated as full stand-alone replace-
208 P. McNamee et al. / Regulatory Toxicology and Pharmacology 54 (2009) 197–209ments for the rabbit Draize eye test. Some assays (organotypic as-
says) are accepted by regulatory authorities for speciﬁc and limited
purposes. Despite a number of extensive validation studies, the
acceptance of in vitro assays by regulatory bodies beyond those ac-
cepted today will require more data and review.
Regulatory accepted and non-validated in vitro assays are used
for the evaluation of eye irritation of ingredients used in cosmetic
products. Conﬁdence in the evaluation of eye irritation potential is
increased by using combinations of assays since they may provide
information over the entire range of irritancy (from non-irritant to
severe) for different classes of chemicals. A combination of the reg-
ulatory accepted and non-validated assays together with all other
available information in a tiered approach which is based on aWoE
evaluation in each step provides a reasonable framework for the
evaluation of eye irritation of ingredients used in cosmetic prod-
ucts. General acceptance of using such an approach is a pre-requi-
site for replacing animal studies.
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